JYNNEOS Vaccine Administration in IgG Deficiency

Classification of IgG Deficiency

Patients with minor antibody deficiencies, such as isolated IgG subclass deficiency, should receive all routine vaccinations, including JYNNEOS, based on the CDC annual schedule, provided other immune components are intact, as recommended by the Centers for Disease Control and Prevention 1, 2
The American Academy of Allergy, Asthma, and Immunology recommends that patients with major antibody deficiencies, such as CVID, avoid all live vaccines, including JYNNEOS, due to potential vaccine-related disease risk 4

The Centers for Disease Control and Prevention recommends assessing the severity of IgG deficiency and evaluating other immune system components, such as T-cell function, complement, and phagocytic function, to determine the safety of JYNNEOS vaccination 1, 2
Patients on immunoglobulin replacement therapy have major antibody deficiency by definition and should avoid live vaccines, including JYNNEOS, as recommended by the Clinical Infectious Diseases society 1, 4

The Clinical Infectious Diseases society recommends a conservative approach for major antibody deficiencies, avoiding JYNNEOS due to theoretical risks, despite its non-replicating nature 1, 4

The American Academy of Allergy, Asthma, and Immunology emphasizes the importance of distinguishing between minor and major antibody deficiencies when considering JYNNEOS vaccination, as patients with isolated IgG subclass deficiency can receive JYNNEOS, while those with CVID cannot 1, 4

The Clinical Infectious Diseases society recommends that household members and close contacts of immunocompromised patients receive all age-appropriate vaccines, including JYNNEOS, to create a protective barrier around the patient 4